From USD 5.1 billion in 2022 to USD 8.9 billion by 2031, the worldwide live attenuated vaccinations market is expected to rise at a CAGR of 7.2%. Over the projected period, North America is predicted to control the market.
Rising incidence of infectious diseases, expanding immunization campaigns, and technological developments in vaccine creation are driving notable expansion in the live attenuated vaccination market. Increasing government campaigns to improve immunization rates—especially in underdeveloped nations—are driving market growth. The COVID-19 epidemic has raised awareness of the need of vaccinations even more and sped up studies and development initiatives in this domain. Still, strict legal rules and the expensive cost of manufacturing vaccines create obstacles for the expansion of the industry.
Market Trend: More attention on combo vaccines
Combining vaccines that offer defense against several diseases in a single dosage is becoming increasingly popular in the live attenuated vaccines market. Reduced frequency of injections, increased patient compliance, and cheaper administration costs are just a few of the benefits combination vaccinations present. Manufacturers of vaccines are spending more and more in research and development to produce unique mix formulations capable of concurrently preventing several infectious diseases. For example, many immunization campaigns throughout the globe now consider the MMR vaccine—which guards against measles, mumps, and rubella—as standard. As doctors and legislators search for more affordable and effective immunization plans to raise public health outcomes, this trend is predicted to remain. New combination vaccinations also help to solve the problem of crowded immunization regimens, especially for populations of children. Consequently, in the next years the market is probably going to see a boom in demand for creative combination live attenuated vaccines.
Market Driver: Rising occurrence of infectious diseases
The live attenuated vaccines market is mostly driven by the global growing frequency of infectious illnesses. Emerging and re-emerging infectious illnesses seriously harm public health and call for sensible preventive action. Controlling and stopping the spread of many infectious illnesses depends critically on live attenuated vaccines, which are well-known for generating powerful and long-lasting immune responses. Pathogens are rapidly spreading thanks in part to factors including population expansion, urbanization, climate change, and more worldwide travel, which makes strong vaccination campaigns desperately needed. Furthermore, the continuous threat of pandemics—as shown by the current COVID-19 epidemic—has raised public knowledge of the need of vaccinations in preserving public health. Worldwide governments and healthcare institutions are stepping up initiatives to enhance immunization campaigns and raise vaccine coverage rates. This increasing focus on disease prevention by vaccination is predicted to generate major demand for live attenuated vaccines across different disease indications, so stimulating market growth in the next years.
Market Restraint: Strict legal rules and safety issues
Strict legal rules and safety issues related to live attenuated vaccines provide major obstacles to the expansion of markets. Because strict safety and efficacy standards imposed by regulatory bodies define the development and licensing process for live attenuated vaccines, it is complicated, time-consuming, and expensive. Though generally safe, these vaccinations include attenuated forms of live pathogens that could produce unpleasant effects in some groups, especially immunocompromised people, or reversion to virulence. To guarantee vaccine safety and efficacy, regulatory authorities need thorough clinical studies and post-marketing surveillance, which drives longer development schedules and higher manufacturing costs. Furthermore influencing market development is public opinion and vaccine hesitation resulting from false information on vaccine safety. To allay these issues and keep public confidence, manufacturers have to make significant investments in quality control systems and ongoing monitoring. Particularly in resource-constrained environments, the necessity of cold chain storage and transit for many live attenuated vaccines further complicates and increases the cost of distribution. These elements taken together contribute to higher vaccination rates and may restrict market penetration in some areas, hence perhaps limiting total market growth.
Live attenuated vaccines market is dominated by viral vaccinations.
With a sizable portion of the total income, viral vaccines account for the biggest section in the live attenuated vaccinations industry. The great global incidence of viral illnesses and the success of live attenuated viral vaccines in generating robust immune responses help to explain this predominance. Under this group are vaccines for diseases including measles, mumps, rubella, influenza, and rotavirus; these are extensively applied in national immunization campaigns all around. Viral live attenuated vaccines' effectiveness in eradicating or greatly lowering the occurrence of illnesses like polio and smallpox has strengthened their relevance in public health campaigns even more. Efforts at constant research and development center on both creating novel viral vaccines for newly emerging dangers and enhancing current ones. The COVID-19 epidemic has also piqued interest in viral vaccine research, maybe resulting in developments advantageous for the larger live attenuated vaccination industry. Furthermore chosen by both healthcare practitioners and people are the viral vaccines segment, which gains from proven manufacturing techniques and a solid record of safety and efficacy. This category is likely to keep its leading position in the live attenuated vaccines market over the forecast period as global health projects keep giving prevention of viral illnesses top priority.
Leading the live attenuated vaccines market is North America.
Currently controlling the worldwide live attenuated vaccines market, North America is likely to keep its dominant position over the forecast period. Advanced healthcare infrastructure, substantial healthcare expenditure, and significant government support of immunization campaigns help to explain this regional supremacy. Particularly the United States is very important in promoting market development in the area since of its strong research and development system and concentration of big vaccine producers. The area gains from well-established immunization programs and strong public knowledge of the need of vaccination. Furthermore helping to promote widespread vaccination are good reimbursement policies and the integration of vaccinations into public health campaigns. With large expenditures in creative platforms and manufacturing techniques, North America also leads in technological innovations in vaccine development and production. The area's proactive attitude to newly developing infectious diseases and its emphasis on preserving high immunization rates help to confirm its place in the worldwide market. North America is likely to remain at the forefront of live attenuated vaccine research, development, and commercialization as the demand for more safer and effective vaccinations keeps rising, hence driving general market expansion.
Intense rivalry among a combination of big pharmaceutical companies, established vaccine manufacturers, and rising biotechnology companies defines the live attenuated vaccines industry. Important players are emphasizing on broadening their product lines by means of strategic alliances and research and development projects. Common approaches used to improve market positions and get access to new technologies are mergers and acquisitions. To guarantee steady supply and satisfy rising worldwide demand, companies are also funding innovative production capabilities. New companies, especially in developing countries, are changing the market scene by increasing competitiveness and stimulating invention that fuels innovation. To maximize manufacturing techniques and lower costs, alliances between contract manufacturing companies and vaccine developers are growingly common. Companies are also emphasizing increasing their geographical presence as the market keeps developing, especially in unexplored countries with great growth potential. Pricing policies, regulatory compliance, and the possibility to land government contracts for major immunization campaigns all affect the competitive dynamics as well.
GlaxoSmithKline plc
Merck & Co., Inc.
Pfizer Inc.
Sanofi Pasteur
Serum Institute of India Pvt. Ltd.
CSL Limited
Emergent BioSolutions Inc.
Johnson & Johnson
AstraZeneca plc
Bavarian Nordic A/S
Takeda Pharmaceutical Company Limited
Valneva SE
Merck & Co., Inc.'s live attenuated influenza vaccine gained FDA clearance for an additional indication in 2023, therefore augmenting its possible market reach.
GlaxoSmithKline plc revealed in 2022 effective Phase III trial findings for its new live attenuated vaccine candidate against respiratory syncytial virus (RSV) in older individuals.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Live Attenuated Vaccines Market (2018 – 2022)
3.2. Global Live Attenuated Vaccines Market (2023 – 2031)
3.2.1. Market Segment By Vaccine Type (2023 – 2031)
3.2.2. Market Segment By Route of Administration (2023 – 2031)
3.2.3. Market Segment By Disease Indication (2023 – 2031)
3.2.4. Market Segment By End User (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Increasing focus on combination vaccines
4.1.2. Growing adoption of needle-free vaccine delivery systems
4.1.3. Rising investment in vaccine research for emerging infectious diseases
4.2. Market Drivers
4.2.1. Rising prevalence of infectious diseases
4.2.2. Increasing government initiatives for immunization programs
4.2.3. Technological advancements in vaccine development
4.3. Market Restraints
4.3.1. Stringent regulatory requirements and safety concerns
4.3.2. High costs associated with vaccine development and production
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY VACCINE TYPE (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Viral Vaccines
5.2. Bacterial Vaccines
6. BY ROUTE OF ADMINISTRATION
6.1. Oral
6.2. Intranasal
6.3. Subcutaneous
6.4. Others
7. BY DISEASE INDICATION
7.1. Measles, Mumps & Rubella
7.2. Influenza
7.3. Rotavirus
7.4. Others
8. BY END USER
8.1. Hospitals
8.2. Clinics
8.3. Research Institutes
8.4. Others
9. GEOGRAPHY
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. South America
9.2.1. Brazil
9.2.2. Argentina
9.2.3. Rest of South America
9.3. Europe
9.3.1. Germany
9.3.2. United Kingdom
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle-East
9.5.1. UAE
9.5.2. Saudi Arabia
9.5.3. Turkey
9.5.4. Rest of Middle East
9.6. Africa
9.6.1. South Africa
9.6.2. Egypt
9.6.3. Rest of Africa
10. COMPETITIVE LANDSCAPE
10.1. Key Developments
10.2. Company Market Share Analysis
10.3. Product Benchmarking
11. SWOT ANALYSIS
12. COMPANY PROFILES
12.1. GlaxoSmithKline plc
12.2. Merck & Co., Inc.
12.3. Pfizer Inc.
12.4. Sanofi Pasteur
12.5. Serum Institute of India Pvt. Ltd.
12.6. CSL Limited
12.7. Emergent BioSolutions Inc.
12.8. Johnson & Johnson
12.9. AstraZeneca plc
12.10. Bavarian Nordic A/S
12.11. Takeda Pharmaceutical Company Limited
12.12. Valneva SE (*LIST NOT EXHAUSTIVE)
13. MARKET OPPORTUNITIES
Viral Vaccines
Bacterial Vaccines
By Route of Administration:
Oral
Intranasal
Subcutaneous
Others
By Disease Indication:
Measles, Mumps & Rubella
Influenza
Rotavirus
Others
By End User:
Hospitals
Clinics
Research Institutes
Others
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
